Applications

TCRm’s are custom, soluble monoclonal antibody products that specifically bind particular MHC-peptide antigen complexes displayed on the surface of cells, mimicking the T-cell receptor. These complexes are highly indicative of vaccine antigen processing or cellular disease status. Receptor Logic, exclusively offers this revolutionary TCRm technology for many applications, including:

Reagents for Immunology Research

Receptor Logic’s TCRm products recognize many peptide antigens used in discovery and product development research. The TCRm’s can immediately integrate into and provide a quantitative baseline for a number of established assays, including:

• Immunocytochemical staining
• Flow cytometry
• ELISA
• Antigen priming
• ELISpot
• Cytotoxic T lymphocyte assays

If you wish to test our antibodies in your research, please contact us for a list of available antibodies and pricing.

back to top

Potency Assay Services

Many forms of chronic disease, including cancers and many forms of infectious disease, show limited response to standard chemotherapeutic and small molecule drug products. New therapies are sought showing higher efficacy and less patient morbidity. The patient’s own immune system offers a powerful tool for the control and elimination of these diseases. These new therapeutic approaches, collectively known as T-cell eliciting or active immunotherapies, rely on the action of cytotoxic T-cell lymphocytes (CTLs) to eliminate diseased cells from the body. CTL’s can be induced by a variety of approaches ranging from injectable vaccines to ex-vivo stimulation of dendritic cells. In spite of great progress in this field, scientific understanding about how active immunotherapies or vaccines work is generally lacking. Unlike traditional chemically compounded drugs, vaccines are produced from organisms, and suitable methods of verifying lot to lot potency (the specific activity of therapy needed to produce a measured, quantitative and clinically relevant effect) continues to be a significant challenge for the FDA and vaccine manufacturers, especially those creating next generation therapeutic vaccines.

Receptor Logic’s TCRm products address this critical question of vaccine and active immunotherapy potency. TCRm technology facilitates immunotherapy product potency measurement at four distinct points:

• Assisting in lead antigen validation
• Demonstrating lot-to-lot consistency of released drug substance
• Providing a stability indicating measurements supporting product shelf-life
• Measurement of specific immune responses in clinical trials.

Please contact us and we will provide a complete description of services offered and explore how TCRm technology may assist your product development efforts.

  Receptor Logic Potency Assay

back to top

Therapeutic and Diagnostic Monoclonal Antibodies

Click to view full illustration

Monoclonal antibodies (mAbs) are the ultimate expression of immunology pioneer Paul Ehrlich’s concept of the “magic bullet&’ compound that “could be made to selectively target a disease causing organism, then deliver a toxin for that organism along with the agent of selectivity.&’ The mAb binds a particular antigenic determinant, or epitope, which allows it to be a highly discriminatory agent between disease-specific antigens and those expressed on normal tissues. Further, antibodies can draw the action of the person’s own immune system to kill the cells bound by the mAbs. There is an urgent need to identify new disease biomarkers that are accessible to antibody therapy. However, efforts to identify new markers have proven to be very difficult. MHC-peptide complexes often highly correlate with disease status and, therefore represent new disease biomarkers. These complexes are specifically targeted by TCRm antibodies and trace tissue distribution with high precision allowing integration in several existing and innovative diagnostic platforms. Further, TCRm antibodies efficiently induce cytotoxic cascades when exposed to cells expressing appropriate MHC-peptide antigen complexes and exert strong and selective anti-tumor activity in industry standard models. If you would like to receive more information and explore the diagnostic and therapeutic applications of TCRm antibodies, please contact us for a full data package.

back to top